SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies. Its lead asset, galinpepimut-S, targets a range of cancers including acute myeloid leukemia and mesothelioma. SELLAS operates in a highly specialized field with strong scientific backing and multiple ongoing trials. It aims to deliver targeted, life-extending treatments to patients with unmet medical needs.